Compare ACADIA Pharmaceuticals Inc. (ACAD) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs 3M Company — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while 3M Company trades at $154.92 (market cap $82.41B). The key difference: 3M Company is far larger — about 18.4× ACADIA Pharmaceuticals Inc.'s market cap, and 3M Company pays a 1.97% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | MMM | |
|---|---|---|
Market Cap | $4.49B | $82.41B |
Sector | Health | Industrials |
52-Week High | $28.06 | $174.61 |
52-Week Low | $20.06 | $141.10 |
Enterprise Value | $3.69B | $90.82B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MMM trades at $158.00, down 1.52% today, with a bullish technical signal driven by moving averages. The company reported three consecutive quarterly EPS beats, with Q2 2026 results expected on July 21, 2026. Strong profitability metrics include a 72.14% ROE and 11.14% net margin, though revenue has declined from 2022 peaks. Recent news highlights partnerships with Airbus and an AI tool launch, supporting operational momentum.
Outlook is mixed: analyst consensus is a Hold with a $148.75 price target below current levels, citing limited AI exposure. Risks include volatile cash flows and high debt. Upside depends on execution of growth initiatives and margin improvement. The stock offers a dividend yield with the next payment on June 12, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
